Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03020680 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of Ubiquinone and Ubiquinol in Older Adults
A Phase 1 study, sponsored by Tufts University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03020680 is a Phase 1 study that has completed, run by Tufts University. The registered enrollment target is 12 participants.
The verdict
NCT03020680, a Phase 1 study, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Coenzyme Q10 (or CoQ10) is a marketed supplement in US even though it can be synthesized in the body via complicated biochemical pathways. It exists in both reduced and oxidized states, namely ubiquinol and ubiquinone, respectively. It is commonly present in all cell membranes. The main function of CoQ10 is to participate in energy production. Further, the reduced form of CoQ10, ubiquinol, is appreciated as an important lipophilic antioxidant to protect free radical induced damages to DNA, lipid, and proteins. Given that older adults have increased production of free radicals, suboptimal antioxidant defenses toward free radicals, and a decreased capability to replenish utilized CoQ10, CoQ10 supplementation can be one of feasible ways to increase CoQ10 status in order adults. Most supplements available for consumers are in the oxidized form. While the ubiquinol form is also available, whether the reduced form will be more effective to replenish CoQ10 status in older subjects remains to be explored. Thus, investigators aimed to examine whether ubiquinol will be more effectively absorbed in older adults with a low antioxidant defense status. To pursue this aim, investigators will conduct a double blind, randomized, crossover design trail with 5 study visits (1 screening visit and 4 study visits). Ten older men (\>55 y, BMI: 25-5 kg/m2) with a compromised antioxidant defenses will be recruited and complete the trial. Eligible subjects will be randomized to receive 200 mg/d ubiquinol or ubiquinone for 2 weeks with 2-week washout between crossover. Ubiquinol and ubiquinone in plasma and immune cells in blood will be assessed to reveal whether the reduced form, ubiquinol, is more absorbable than the oxidized form, ubiquinone in older adults.
Interventions
- DIETARY_SUPPLEMENT Coenzyme Q10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03020680
The ClinicalTrials.gov registry entry for NCT03020680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Coenzyme Q10 is the first listed.
NCT03020680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03020680 about?
NCT03020680 is a clinical study titled "Bioavailability of Ubiquinone and Ubiquinol in Older Adults". Coenzyme Q10 (or CoQ10) is a marketed supplement in US even though it can be synthesized in the body via complicated biochemical pathways. It exists in both reduced and oxidized states, namely ubiquinol and ubiquinone, respectively. It is commonly present in all cell membranes. The main function of ...
What is the current status of trial NCT03020680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-04-01. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT03020680?
The interventions under investigation include: Coenzyme Q10 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03020680?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.